- Odulimomab
-
Odulimomab ? Monoclonal antibody Type Whole antibody Source Mouse Target CD11a Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 159445-64-4 ATC code None Chemical data Formula ? (what is this?) (verify) Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]
It is a mouse monoclonal antibody directed against the alpha chain of the protein lymphocyte function-associated antigen 1 which is involved in immune reactions.[1]
References
- ^ a b Martin, X; Da Silva, M; Virieux, SR; Hadj Aissa, A; Buffet, R; Tiollier, J; Dubernard, JM (2000). "Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation". Transplantation proceedings 32 (2): 481. doi:10.1016/S0041-1345(00)00849-6. PMID 10715487.
- ^ Crétolle-Vastel, C; Camby, C; Cerf-Bensussan, N; Cavazzana-Calvo, M; Fischer, A; Révillon, Y; Sarnacki, S (1999). "Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice". Chirurgie; memoires de l'Academie de chirurgie 124 (5): 503–10. PMID 10615777.
- ^ Whitcup, SM; Chan, CC; Kozhich, AT; Magone, MT (1999). "Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis". Clinical immunology (Orlando, Fla.) 93 (2): 107–13. doi:10.1006/clim.1999.4775. PMID 10527686.
- ^ Corbascio, M; Mahanty, H; Osterholm, C; Qi, Z; Pearson, TC; Larsen, CP; Freise, CE; Ekberg, H (2002). "Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice". Transplantation 74 (1): 35–41. doi:10.1097/00007890-200207150-00007. PMID 12134096.
Monoclonal antibodies for the immune system Immune system ("-l(i[m])-") Human ("-limu-")immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab
immune activation: Ipilimumab • Tremelimumab
other: Bertilimumab • ZanolimumabMouse ("-limo-")Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritoxChimeric ("-lixi-")Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • VapaliximabHumanized ("-lizu-")immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†Chimeric + humanized
("-lixizu-")Interleukin ("-k(i[n])-") Human ("-kinu-")Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • UstekinumabHumanized ("-kizu-", "-kinzu-")Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • OlokizumabInflammatory lesions ("-les-") Mouse ("-leso-")This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.